Statements (58)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:biotechnology
|
| gptkbp:acquisition |
gptkb:Archer_DX
gptkb:Gene_Dx Cure Match Lifecode Myriad Genetics' my Risk |
| gptkbp:awards |
various industry recognitions
|
| gptkbp:business_model |
direct-to-consumer
physician-ordered testing |
| gptkbp:ceo |
Sean George
|
| gptkbp:challenges |
market competition
regulatory hurdles reimbursement issues |
| gptkbp:clinical_trial |
yes
|
| gptkbp:collaboration |
academic institutions
pharmaceutical companies |
| gptkbp:community_engagement |
gptkb:educational_programs
patient advocacy groups healthcare initiatives |
| gptkbp:employees |
over 1,000
|
| gptkbp:financial_support |
gptkb:financial_assistance
genetic counseling insurance verification |
| gptkbp:focus |
gptkb:Oncology
rare diseases hereditary conditions |
| gptkbp:founded |
gptkb:2010
|
| gptkbp:founder |
Sean George
|
| gptkbp:future_plans |
international growth
partnerships with healthcare systems expansion of test offerings |
| gptkbp:headquarters |
gptkb:San_Francisco,_California
|
| https://www.w3.org/2000/01/rdf-schema#label |
Invitae Corporation
|
| gptkbp:industry |
genetic testing
|
| gptkbp:market |
gptkb:Europe
gptkb:Asia gptkb:North_America |
| gptkbp:mission |
to bring comprehensive genetic information into mainstream medicine.
|
| gptkbp:partnership |
healthcare providers
various healthcare organizations |
| gptkbp:provides_information_on |
genetic data
|
| gptkbp:regulatory_compliance |
FDA approved tests
|
| gptkbp:research |
population genetics
clinical outcomes disease associations genetic variants |
| gptkbp:revenue |
$200 million (2020)
|
| gptkbp:services |
genetic information
|
| gptkbp:stock_exchange |
yes
|
| gptkbp:stock_symbol |
NVTA
|
| gptkbp:technology |
next-generation sequencing
|
| gptkbp:test_offerings |
diagnostic testing
pharmacogenomics carrier screening predictive testing |
| gptkbp:website |
www.invitae.com
|
| gptkbp:bfsParent |
gptkb:Archer_DX
|
| gptkbp:bfsLayer |
5
|